

Vietnam's National Vaccine Company (VNVC) begins manufacturing unit construction with \$77M initial investment

28 May 2025 | News

The facility is anticipated to be completed by 2027 with capacity of up to 100 million vaccine doses per year



VNVC Vaccine and Biological Products Factory in Long An Province, in southern Vietnam, has begun construction on its 26,000 square meter factory building with an investment of VND2 trillion (US\$77.17 million).

The new facility, with capacity of up to 100 million vaccine doses per year, represents a major advance in Vietnam's capability to produce and supply vaccines locally. The facility is anticipated to be completed by 2027 and will receive technology transfer from Sanofi, which will prioritise localisation of new and important vaccines.

On May 27, France's President Emmanuel Macron and Vietnamese Vice President Vo Thi Anh Xuan attended the groundbreaking ceremony, which was part of President Macron's state visit to Vietnam. Vaccine company chairman and CEO Ngo Chi Dung said the new factory will reduce costs, ensure a proactive domestic supply, support exports, and enable participation in the global vaccine supply chain, contributing to Vietnam's health security.

In addition to research and development facilities, animal laboratories, and production lines for vaccines and biological products using multiple technologies, the factory will house various sub-areas. A total of three lines including an isolator technology line and a filling line for injection pens will be installed in the beginning. Vaccine production lines have been designed for flexible conversion, making it possible to produce both mass vaccine production and focused vaccine production, which is crucial for responding to urgent public health needs, including new pandemics.

The project is designed to meet the highest international standards, including European Good Manufacturing Practice (EU GMP), US FDA GMP, and World Health Organization (WHO) GMP. It also strictly complies with Good Laboratory Practice (GLP) and international animal welfare standards (AAALAC), as well as numerous requirements for environmental protection and emissions reduction.

VNVC is also investing in a 1,500-square-meter Research and Development Center (R&D) focused on advanced vaccine and biological production technologies, particularly mRNA vaccines. In Vietnam, the center plans to collaborate with experts,

universities, and pharmaceutical companies to conduct preclinical and clinical trials, giving the public early access to new drugs and vaccines.

Since launching its vaccine system in 2017, VNVC Vaccine Company has provided nearly 50 types of vaccines and has prevented nearly 50 infectious diseases, including diseases for which vaccines are often scarce. Vietnam's National Vaccine Company (VNVC) has contributed to the protection of millions of Vietnamese against dengue fever and meningococcal B.